Regulation of Sirtuin-Mediated Protein Deacetylation by Cardioprotective Phytochemicals

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Treviño Saldaña, Niria ^a   García Rivas, Gerardo ^a,b  

^a SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^b HOSPITAL ZAMBRANO HELLION   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; DISEASES; MODULATION; PROTEINS;

ACETYLTRANSFERASES; CARDIAC HYPERTROPHY; CARDIO-VASCULAR DISEASE; CARDIOPROTECTIVE EFFECT; DOCOSAHEXAENOIC ACID; EPIGALLOCATECHIN-3-GALLATE; POST-TRANSLATIONAL MODIFICATIONS; THERAPEUTIC STRATEGY;

ACETYLATION;

ACYLTRANSFERASE; BAKUCHIOL; BERBERINE; CAFFEIC ACID; CURCUMIN; DOCOSAHEXAENOIC ACID; EPIGALLOCATECHIN GALLATE; ETHANOLAMIDE; HONOKIOL; OROXILYN A; PHENOL DERIVATIVE; PHYTOCHEMICAL; QUERCETIN; RESVERATROL; SIRTUIN; SIRTUIN 1; SIRTUIN 3; SULFORAPHANE; THIOCTIC ACID; TYROSOL; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; DRUG BIOAVAILABILITY; ENZYME INHIBITION; HEART PROTECTION; HUMAN; NONHUMAN; PROTEIN ACETYLATION; PROTEIN FUNCTION; REVIEW; ACETYLATION; METABOLISM;

ACETYLATION; DISEASES; PROTEINS;

ACETYLATION; HUMANS; PHYTOCHEMICALS; SIRTUINS;

EID: 85040682445     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/1750306     Document Type: Review

References (119)

1. D. Mozaffarian, E. J. Benjamin, A. S. Go et al., "Heart disease and stroke statistics-2015 update: a report from the American Heart Association," Circulation, vol. 131, pp. e29-e322, 2015.
2. World Health Organization, Global Atlas on Cardiovascular Disease Prevention and Control, S. Mendis, P. Puska and B. Norrving, Eds., Geneva, 2011, Obtained from http://www.who.int/cardiovascular-diseases/publications/ atlas-cvd/en/.
3. S. A. Egert and J. Bosy-Westphal, "Seiberl. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a doubleblinded, placebo-controlled cross-over study," British Journal of Nutrition, vol. 7, no. 102, pp. 1065-1074, 2009.
4. V. Faridi, S. Njike, A. Dutta, D. Ali, and D. Katz, "Acute dark chocolate and cocoa ingestion and endothelial function: a randomized controlled crossover trial," The American Journal of Clinical Nutrition, vol. 1, no. 88, pp. 58-63, 2008.
5. G. García-Rivas, K. A. Youker, C. Orrego et al., "Standardized extract from black bean coat (Phaseolus vulgaris L.) prevents adverse cardiac remodeling in a murine model of nonischemic cardiomyopathy," RSC Advances, vol. 5, pp. 90858-90865, 2015.
6. D. Rodríguez-Sánchez, C. Silva-Platas, R. P. Rojo et al., "Activity-guided identification of acetogenins as novel lipophilic antioxidants present in avocado pulp (Persea americana)," Journal of Chromatography B, vol. 30, pp. 942-943, 2013.
7. D. G. Rodriguez-Sanchez, M. Flores-García, C. Silva-Platas et al., "Isolation and chemical identification of lipid derivatives from avocado (Persea americana) pulp with antiplatelet and antithrombotic activities," Food &Function, vol. 6, no. 1, pp. 193-203, 2001.
8. J. L. Horton, O. J. Martin, L. Lai et al., "Mitochondrial protein hyperacetylation in the failing heart," JCI Insight, vol. 2, article e84897, 2016.
9. S. M. Nadtochiy, E. Redman, I. Rahman, and P. S. Brookes, "Lysine deacetylation in ischaemic preconditioning: the role of SIRT1," Cardiovascular Research, vol. 89, pp. 643-649, 2011.
10. A. Bong-Hyun, K. Hyun-Seok, S. Shiwei et al., "A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, pp. 14447-14452, 2008.
11. C. T. Walsh, S. Graneau-Tsodikova, and G. J. Gatto, "Protein posttranslational modifications: the chemistry of proteome diversifications," Angewandte Chemie (International Ed. in English), vol. 45, pp. 7342-7372, 2005.
12. E. Verdin and M. Ott, "50 years of protein acetylation: from gene regulation to epigenetics; metabolism and beyond," Nature Reviews Molecular Cell Biology, vol. 16, no. 4, pp. 258-264, 2014.
13. V. G. Allfrey, R. Faulkner, and A. E. Mirsky, "Acetylation and methylation of histones and their possible role in the regulation of Rna synthesis," Proceedings of the National Academy of Sciences, vol. 51, pp. 786-794, 1964.
14. L. Su-ju, M. Kaeberlein, A. A. Andalis et al., "Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration," Nature, vol. 418, pp. 344-348, 2002.
15. C. B. Brachmann, J. M. Sherman, S. E. Devine, E. E. Cameron, L. Pillus, and J. D. Boeke, "The SIR2 gene family; conserved from bacteria to humans; functions in silencing; cell cycle progression; and chromosome stability," Genes Development, vol. 23, pp. 2888-2902, 1995.
16. S. Michan and R. D. Sinclai, "Sirtuins in mammals: insights into their biological function," Biochemical Journal, vol. 404, no. 1, pp. 1-13, 2007.
17. K. T. Howitz, K. J. Bitterman, H. Cohen et al., "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan," Nature, vol. 425, pp. 191-196, 2003.
18. R. A. Frye, "Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADPribosyltransferase activity," Biochemical and Biophysical Research Communications, vol. 260, pp. 273-279, 1999.
19. R. A. Frye, "Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins," Biochemical and Biophysical Research Communications, vol. 273, pp. 793-798, 2000.
20. J. J. Smith, R. D. Kenney, D. J. Gagne et al., "Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo," BMC Systems Biology, vol. 10, p. 31, 2009.
21. F. Flick and B. Luscher, "Regulation of sirtuin function by posttranslational modifications," Frontiers in Pharmacology, vol. 3, p. 29, 2012.
22. M. C. Haigis, R. Mostoslavsky, K. Haigis et al., "SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic β cells," Cell, vol. 126, pp. 941-954, 2006.
23. J. Du, Y. Zhou, X. Su et al., "Sirt5 is an NAD-dependent protein lysine demalonylase and desuccinylase," Science, vol. 334, no. 6057, pp. 806-809, 2016.
24. X. Zhu, Q. Lui, M. Wang et al., "Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts," PLoS One, vol. 6, no. 11, article e27081, 2011.
25. S. Xu, M. Yin, M. Koroleva et al., "SIRT6 protects against endothelial dysfunction and atherosclerosis in mice," Aging, vol. 8, no. 5, pp. 1064-1078, 2016.
26. S. B. Jung, S. K. Kwon, M. Kwon et al., "Docosahexaenoic acid improves vascular function via up-regulation of SIRT1 expression in endothelial cells," Biochemical and Biophysical Research Communications, vol. 437, pp. 114-119, 2013.
27. T. Walle, F. Hsieh, H. M. DeLegge, J. E. Oatis, and U. K. Walle, "High absorption but very low bioavailability or oral resveratrol in humans," Drug Metabolism and Disposition, vol. 23, no. 12, pp. 1377-1382, 2004.
28. K. Higashida, S. H. Kim, S. R. Jung, M. Asaka, J. O. Holloszy, and H. Dong-Ho, "Effects of resveratrol and SIRT1 on PGC-1α activity and mitochondrial biogenesis: a reevaluation," PLoS Biology, vol. 12, no. 1, p. 10, 2014.
29. D. B. Lombard, F. W. Alt, H. L. Cheng et al., "Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation," Molecular and Celullar Biology, vol. 24, pp. 8807-8814, 2007.
30. B. H. Ahn, H. S. Kim, S. Song et al., "A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis," Proceedings of the National Academy of Sciences, vol. 38, pp. 14447-14452, 2008.
31. A. V. Hafner, J. Dai, A. P. Gomes et al., "Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy," Aging, vol. 2, no. 12, pp. 914-923, 2010.
32. G. A. Porter, R. U. William, P. S. Brookes, and S. M. Nadtochy, "SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts," American Journal of Physiology Heart and Circulatory Physiology, vol. 306, pp. H1602-H1609, 2014.
33. L. Yang, B. Vaitheesvaran, K. Hartil et al., "N6-acetylation differences suggest acetylation coordinates organ-specific fuel switching," Journal of Proteome Research, vol. 10, no. 9, pp. 4134-4149, 2011.
34. X. He, H. Zeng, and J. X. Chen, "Ablation of SIRT3 causes coronary microvascular dysfunction and impairs cardiac recovery post myocardial ischemia," International Journal of Cardiology, vol. 215, pp. 349-357, 2016.
35. R. M. Parodi-Rullán, X. Chapa-Dubocq, P. J. Rullán, S. Jang, and S. Javadov, "High sensitivity of SIRT3 deficient hearts to ischemia-reperfusion is associated with mitochondrial abnormalities," Frontiers in Pharmacology, vol. 16, no. 8, p. 275, 2017, 14447-14452.
36. N. R. Sundersan, M. Gupta, G. Kim, S. B. Rajamohan, A. Isbatan, and M. P. Gupta, "Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice," Journal of Clinical Investigation, vol. 119, no. 9, pp. 2758-2771, 2009.
37. V. B. Pillai, S. Samant, N. R. Sundersan et al., "Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3," Nature Communications, vol. 6, p. 6656, 2015.
38. K. G. Cheung, L. K. Cole, B. Xiang et al., "Sirtuin-3 (SIRT3) protein attenuates doxorubicin-induced oxidative stress and improves mitochondrial respiration in H9c2 cardiomyocytes," The Journal of Biological Chemistry, vol. 290, pp. 10981-10993, 2015.
39. Y. Kobayashi, Y. Furukawa-Hibi, C. Chen et al., "SIRT1 is critical regulator of FoxO-mediated transcription in response to oxidative stress," International Journal of Molecular Medicine, vol. 16, no. 2, pp. 237-243, 2005.
40. T. K. Sin, A. P. Yu, B. Y. Yung et al., "Modulating effect of SIRT1 activation induced by resveratrol on FoxO1-associated apoptotic signalling in senescent heart," The Journal of Physiology, vol. 592, no. 12, pp. 2535-2548, 2014.
41. C. H. Lin, C. C. Lin, W. J. Ting et al., "Resveratrol enhanced FoxO3 phosphorylation via synergetic activation of SIRT1 and PI3K/Akt signaling to improve the effects of exercise in elderly rat hearts," AGE, vol. 36, p. 9705, 2014.
42. Y. Yang, W. Duan, Y. Lin et al., "SIRT1 activation by curcumin pretreatment attenuates mitochondrial oxidative damage induced by myocardial ischemia reperfusion injury," Free Radical Biology &Medicine, vol. 65, pp. 667-679, 2013.
43. M. W. McBurney, X. Yang, K. Jardine et al., "The mammalian SIR2α protein has a role in embryogenesis and gametogenesis," Molecular and Cellular Biology, vol. 23, no. 1, pp. 38-54, 2003.
44. A. Planavila, E. Dominguez, M. Navarro et al., "Dilated cardiomyopathy and mitochondrial dysfunction in Sirt1-deficient mice: a role for Sirt1-Mef2 in adult heart," Journal Molecular and Cellular Biology, vol. 53, no. 4, pp. 521-531, 2012.
45. C. P. Hsu, P. Zhai, T. Yamamoto et al., "Silent information regulator 1 protects the heart from ischemia/reperfusion," Circulation, vol. 122, no. 21, pp. 2170-2182, 2010.
46. X.-H. Guan, X.-H. Liu, X. Hong et al., "CD38 deficiency protects the heart from ischemia/reperfusion injury through activating SIRT1/FOXOs-mediated antioxidative stress pathway," Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 7410257, 14 pages, 2016.
47. P. T. Pfluger, D. Herranz, S. Velasco-Miguel, M. Serrano, and M. H. Tschop, "Sirt1 protects against high-fat dietinduced metabolic damage," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, pp. 9793-9798, 2008.
48. R. R. Alcendor, S. Gao, P. Zhai et al., "Sirt1 regulates aging and resistance to oxidative stress in the heart," Circulation Research, vol. 100, no. 10, pp. 1512-1521, 2007.
49. Y. Ruan, C. Dong, J. Patel et al., "SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways," Cellular Physiology and Biochemistry, vol. 35, pp. 1116-1124, 2015.
50. A. Prola, J. P. Da Silva, A. Guilbert et al., "SIRT1 protects the heart from ER stress-induced cell death through eIF2α deacetylation," Cell Death &Differentiation, vol. 24, pp. 343-356, 2017.
51. A. M. Thompson, K. A. Martin, and E. M. Rzucidlo, "Resveratrol induces vascular smooth muscle cell differentiation through stimulation of SirT1 and AMPK," PLos One, vol. 9, no. 1, article e85495, 2014.
52. M. Tanno, A. Kuno, T. Yano et al., "Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure," The Journal of Biological Chemistry, vol. 285, pp. 8375-8382, 2010.
53. C. Tongshuai, L. Jingyuan, L. Junni et al., "Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGFB/Smad3 pathway," The American Journal of Physiology, vol. 308, pp. H424-H434, 2015.
54. B. P. Hubbard, "Evidence for a common mechanism of SIRT1 regulation by allosteric activators," Science, vol. 339, pp. 1216-1219, 2013.
55. R. R. Alcendor, L. A. Kirshenbaum, S. Imai, S. F. Vatner, and J. Sadoshima, "Silent information regulator 2α a longevity factor and class III histone deacetylase; is an essential endogenous apoptosis inhibitor in cardiac myocytes," Circulation Research, vol. 95, no. 10, pp. 971-980, 2004.
56. Y. Lou, Z. Wang, Y. Xu et al., "Resveratrol prevents doxorubicin-induced cardiotoxicity in H9c2 cells through the inhibition of endoplasmic reticulum stress and the activation of the Sirt1 pathway," International Journal of Molecular Medicine, vol. 36, pp. 873-880, 2015.
57. C. Zhang, Y. Feng, S. Qu et al., "Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53," Cardiovascular Research, vol. 90, pp. 538-545, 2011.
58. T. K. Sin, B. T. Tam, B. Y. Yung et al., "Resveratrol protects against doxorubicin-induced cardiotoxicity in aged hearts through the SIRT1-USP7 axis," The Journal of Physiology, vol. 593, no. 8, pp. 1887-1899, 2015.
59. Z. Ungvari, N. Labinskyy, P. Mukhopadhyay et al., "Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells," The American Journal of Physiology, vol. 2009, no. 297, pp. H1876-H1881, 2009.
60. S. J. Thandapilly, X. L. Louis, T. Yang et al., "Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes; by activating NO-AMPK pathway," European Journal of Pharmacology, vol. 668, no. 1-2, pp. 217-224, 2011.
61. P. K. Bagul, A. K. Dinda, and S. K. Banerjee, "Effect of resveratrol on sirtuins expression and cardiac complications in diabetes," Biochemical and Biophysical Research Communications, vol. 468, pp. 221-227, 2015.
62. W. Yu, Y. C. Fu, X. H. Zhou et al., "Effects of resveratrol on H2O2-induced apoptosis and expression of SIRTs in H9c2 cells," Journal of Cellular Biochemistry, vol. 107, pp. 741-747, 2009.
63. N. Xia, A. Daiber, A. Habermeier et al., "Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice," Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 149-154, 2010.
64. T. Kawashima, Y. Inuzuka, J. Okuda et al., "Constitutive SIRT1 overexpression impairs mitochondria and reduces cardiac function in mice," Journal of Molecular and Cellular Cardiology, vol. 51, no. 6, pp. 1026-1036, 2011.
65. G. J. García-Rivas and G. Torre-Amione, "Abnormal mitochondrial function during ischemia reperfusion provides targets for pharmacological therapy," Methodist DeBakey Cardiovascular Journal, vol. 5, no. 3, pp. 2-7, 2009.
66. G. Garcia-Rivas, J. A. Morales, L. Vega-Sevilla, C. Silva-Platas, and N. García, "Regulation of mitochondrial permeability transition by Sirt3-catalyzed cyclophilin D deacetylation and its relevance for ventricular dysfunction in metabolic syndrome," Mitochondr Physiol Network, vol. 18, no. 08, 2013.
67. G. Karamanlidis, C. F. Lee, L. Garcia-Menendez et al., "Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure," Cell Metabolism, vol. 18, pp. 239-25045d, 2013.
68. C. F. Lee, J. D. Chavez, L. Garcia-Menendez et al., "Normalization of NAD+ redox balance as a therapy for heart failure," Circulation, vol. 134, no. 12, pp. 883-894, 2016.
69. N. R. Sundersan, P. Vasudevan, L. Zhong et al., "The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun," Nature Medicine, vol. 18, pp. 1643-1650, 2012.
70. X. Wen and T. Walle, "Methylated flavonoids have greatly improved intestinal absorption and metabolic stability," Drug Metabolism &Disposition, vol. 34, pp. 1786-1792, 2006.
71. C. Canto, R. H. Houtkooper, E. Pirinen et al., "The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity," Cell Metabolism, vol. 15, no. 6, pp. 838-847, 2012.
72. J. Camacho-Pereira, M. G. Tarragó, C. C. Chini et al., "CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism," Cell Metabolism, vol. 23, no. 6, pp. 1127-1139, 2016.
73. M. S. Bonkowski and D. A. Sinclair, "Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds," Nature Reviews Molecular Cell Biology, vol. 17, pp. 679-690, 2016.
74. S. Matsushima and J. Sadoshima, "The role of sirtuins in cardiac disease," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 309, no. 9, pp. H1375-H1389, 2015.
75. M. Pacholec, J. E. Bleasdalle, B. Chrunyk et al., "SRT1720; SRT2183; SRT1460; and resveratrol are not direct activators of SIRT1," The Journal of Biological Chemistry, vol. 285, pp. 8340-8835, 2009.
76. W. Hong, S. Tatsuo, W. Shou-Dong, Z. Qian, H. Jian-Feng, and W. Jue, "Resveratrol upregulates cardiac SDF-1 in mice with acute myocardial infarction through the deacetylation of cardiac p53," PLoS One, vol. 10, no. 6, article e0128978, 2015.
77. J. Xiao, C. Sheng, X. Zhang, M. Guo, and X. Ji, "Curcumin protects against myocardial infarction-induced cardiac fibrosis via SIRT1 activation in vivo and in vitro," Drug Design; Development and Therapy, vol. 10, pp. 1267-1277, 2016.
78. X.-l. Lin, M.-H. Liu, H.-J. Hu et al., "Curcumin enhanced cholesterol efflux by upregulating ABCA1 expression through AMPK-SIRT1-LXRa signaling in THP-1 macrophage-derived foam cells," DNA and Cell Biology, vol. 34, pp. 561-572, 2015.
79. Y. Sun, X. Hu, G. Hu, C. Xu, and H. Jiang, "Curcumin attenuates hydrogen peroxide-induced premature senescence via the activation of SIRT1 in human umbilical vein endothelial cells," Biological and Pharmaceutical Bulletin, vol. 38, pp. 1134-1141, 2015.
80. T. Morimoto, Y. Sunagawa, T. Kawamura et al., "The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats," Journal of Clinical Investigation, vol. 118, pp. 868-878, 2008.
81. A. Bugyei-Twim, A. Advani, S. L. Advani et al., "Highglucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy," Cardiovascular Diabetology, vol. 13, p. 89, 2014.
82. A. Ray, S. Rana, D. Banerjee et al., "Improved bioavailability of targeted curcumin delivery efficiently regressed cardiac hypertrophy by modulating apoptotic load within cardiac microenvironment," Toxicology and Applied Pharmacology, vol. 290, pp. 54-65, 2016.
83. R. Chowdhury, R. Nimmanapalli, T. Graham, and G. Reddy, "Curcumin attenuation of lipopolysaccharide induced cardiac hypertrophy in rodents," ISRN Inflammation, vol. 2013, Article ID 539305, 8 pages, 2013.
84. S. Nehra, V. Bhardwaj, L. Ganju,andD.Saraswat, "Nanocurcuminpreventshypoxiainducedstressinprimaryhumanventricular cardiomyocytes by maintaining mitochondrial homeostasis," PLoSOne, vol. 10, no. 9, article e0139121, 2015.
85. T. Li, Z. Feng, M. Yao, Q. Liao, Z. Zhongxiang, and L. Zheng, "Comparative pharmacokinetic and tissue distribution study of baicalin; baicalein; wogonoside; wogonin and oroxylin-A after oral administration of component compatibility of SHT and total flavonoids fractions of Radix scutellariae to rats," Analytical Methods, vol. 6, pp. 5799-5807, 2014.
86. L. Wei, Y. Zhou, Q. Dai et al., "Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma," Cell Death &Disease, vol. 4, article e601, 2013.
87. N. Hu, J. Ren, and Y. Zhang, "Mitochondrial aldehyde dehydrogenase obliterates insulin resistance-induced cardiac dysfunction through deacetylation of PGC-1α," Oncotarget, vol. 7, pp. 76398-76414, 2016.
88. N. Treviño-Saldaña and J. G. García-Rivas, Cardioprotective Effect of Oroxylin A as as Modulator of Mitochondrial Protein Acetylation in a Model of Hypertrophy and Cell Injury, ISHR conference meeting, New Orleans, LA, USA, 2017.
89. J. Liu, Y. Tang, Z. Feng et al., "Acetylated FoxO1 mediates high-glucose induced autophagy in H9c2 cardiomyoblasts: regulation by a polyphenol-(-)-epigallocatechin-3-gallate," Metabolism Clinical and Experimental, vol. 63, pp. 1314-1323, 2014.
90. W. Zhong, X. D. Huan, Q. Cao, and J. Yang, "Cardioprotective effect of epigallocatechin-3-gallate against myocardial infarction in hypercholesterolemic rats," Experimental and therapeutic Medicine, vol. 9, pp. 405-410, 2015.
91. H. Chan, P. M. Chu, and K. L. Tsai, "Quercetin is a potent anti-atherosclerotic compound by activation of SIRT1 signaling under oxLDL stimulation," Molecular Nutrition &Food Research, vol. 59, pp. 1905-1917, 2015.
92. L. Yu, Q. Li, B. Yu et al., "Berberine attenuates myocardial ischemia/reperfusion injury by reducing oxidative stress and inflammation response: role of silent information regulator 1," Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1689602, 16 pages, 2016.
93. J. Feng, Y. Yang, Y. Zhou et al., "Bakuchiol attenuates myocardial ischemia reperfusion injury by maintaining mitochondrial function: the role of silent information regulator 1," Apoptosis, vol. 21, pp. 532-545, 2016.
94. M. S. Samson, T. Mahesh, V. P. Suresh, P. Debayon, and M. Nilanjana, "Akt/FOXO3a/SIRT1 mediated cardioprotection by n-tyrosol against ischemic stress in rat in vivo model of myocardial infarction: switching gears towards survival and longevity," Journal of Agricultural and Food Chemistry, vol. 56, no. 20, pp. 9692-9698, 2008.
95. L. Zhang, J. Zou, E. Chai, Y. Qi, and Y. Zhang, "Alpha-lipoic acid attenuates cardiac hypertrophy via downregulation of PARP-2 and subsequent activation of SIRT-1," European Journal of Pharmacology, vol. 744, pp. 203-210, 2014.
96. Z. Zhang, S. Wang, S. Zhou et al., "Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway," Journal of Molecular and Cellular Cardiology, vol. 77, pp. 42-52, 2014.
97. S. Y. Lee, H. C. Ku, Y. H. Kuo et al., "Caffeic acid ethanolamide prevents cardiac dysfunction through sirtuin dependent cardiac bioenergetics preservation," Journal of Biomedical Science, vol. 22, p. 80, 2015.
98. S. Timmers, E. Konings, L. Bilet et al., "Calorie restriction-like effects of 30 days of resveratrol (resVidaTM) supplementation on energy metabolism and metabolic profile in obese humans," Cell Metabolism, vol. 5, p. 14, 2011.
99. L. Gliemann, J. F. Schmidt, J. Olesen et al., "Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men," The Journal of Physiology, vol. 591, no. 20, pp. 5047-5059, 2013.
100. P. Skrobuk, S. von Kraemer, M. M. Semenova, A. Zitting, and H. A. Koistinen, "Acute exposure to resveratrol inhibits AMPK activity in human skeletal muscle cells," Diabetologia, vol. 11, pp. 3051-3060, 2012.
101. J. Yoshino, C. Conte, L. Fontana et al., "Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance," Cell Metabolism, vol. 16, no. 5, p. 658, 2012.
102. M. D. Hirschey, T. Shimazu, E. Jing et al., "SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome," Molecular Cell, vol. 44, no. 2, pp. 177-190, 2011.
103. CRN, B vitamins and Cardiovascular Disease, The Benefits of Nutritional Supplements, Washington, DC, USA, 4th edition, 2012, https://www.crnusa.org/sites/default/files/ pdfs-benefits/14CRN-BenefitsBook-Bcvd.pdf.
104. X. Wen and T. Walle, "Methylated flavonoids have greatly improved intestinal absorption and metabolic stability," Drug Metabolism and Disposition, no. 34, pp. 1786-1792, 2006.
105. C. Manach, S. Scalbert, C. Morand, C. Remesy, and L. Jiménez, "Polyphenols: food sources and bioavailability," The American Journal of Clinical Nutrition, vol. 79, pp. 727-747, 2004.
106. H. Surangi and V. Rupasinghe, "Flavonoid bioavailability and attempts for bioavailability enhacement," Nutrients, vol. 5, pp. 3367-3387, 2013.
107. C. E. Guerrero-Beltrán, J. Bernal-Ramírez, O. Lozano et al., "Silica nanoparticles induce cardiotoxicity interfering with energetic status and Ca2+ handling in adult rat cardiomyocytes," American Journal of Physiology. Heart and Circulatory Physiology, vol. 312, no. 4, p. H645, 2017.
108. G. U. Ruiz-Esparza, V. Segura-Ibarra, A. M. Cordero-Reyes et al., "A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics," European Journal of Heart Failure, vol. 18, no. 2, pp. 169-178, 2016.
109. C. M. Guinane and P. D. Cotter, "Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ," Therapeutic Advances in Gastroenterology, vol. 6, pp. 295-308, 2013.
110. T. Ozdal, D. A. Sela, J. Xiao, D. Boyacioglu, F. Chen, and E. Capanoglu, "The reciprocal interactions between polyphenols and gut microbiota and effects on bioaccessibility," Nutrients, vol. 8, p. 78, 2016.
111. I. Sekirov, C. L. Russel, C. M. Antunes, and B. Finlay, "Gut microbiota in health and disease," Physiological Reviews, vol. 90, pp. 859-904, 2010.
112. J. Bouayed and T. Bohn, "Exogenous antioxidants: doubleedged swords in cellular redox state," Oxidative Medicine and Cellular Longevity, vol. 3, no. 4, pp. 228-237, 2010.
113. B. Juhasz, S. Mukherjee, K. Dipak, and D. K. Das, "Hormetic response of resveratrol against cardioprotection," Experimental &Clinical Cardiology, vol. 15, no. 4, pp. e134-e138, 2010.
114. D. J. Boocock, G. E. Faust, K. R. Patel et al., "Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential chemopreventive agent," Cancer Epidemiology, Biomarkers &Prevention, vol. 16, no. 6, pp. 1246-1252, 2007.
115. S. D. Anton, C. Embry, M. Marsiske et al., "Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study," Experimental Gerentology, vol. 57, pp. 181-187, 2014.
116. M. Vignes, T. Maurice, F. Lante, M. Nedjar, K. Thethi, and J. Guiramand, "Anxiolytic properties of green tea polyphenol (-)-epigallocatechin gallate (EGCG)," Brain Research, vol. 1110, pp. 102-115, 2006.
117. L. Almeida, M. Vaz-da-Silva, A. Falcão, and E. Soares, "Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers," Molecular Nutrition &Food Research, vol. 53, pp. S7-S1, 2009.
118. Y. Kinjo, Y. Cui, S. Akiba, and S. Watanabe, "Mortality risks of oesophageal cancer associated with hot tea, alcohol, tobacco and diet in Japan," Journal of Epidemiology, vol. 8, pp. 235-243, 1998.
119. F. Islami, P. Boffetta, and J. RenL. Pedoeim, "High-temperature beverages and foods and esophageal cancer risk-A systematic review," International Journal of Cancer, vol. 125, pp. 491-524, 2009.